Literature DB >> 29162611

High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.

Majken K Jensen1,2, Sarah A Aroner3, Kenneth J Mukamal4, Jeremy D Furtado3, Wendy S Post5, Michael Y Tsai6, Anne Tjønneland7, Joseph F Polak8, Eric B Rimm3,9,2, Kim Overvad10, Robyn L McClelland11, Frank M Sacks3,2.   

Abstract

BACKGROUND: The causal role of high-density lipoprotein (HDL) cholesterol in cardioprotection has been questioned by genetic and randomized studies. Novel measures that relate to HDL function may contribute new information to the prediction of cardiovascular risk. Apolipoprotein C-III (apoC-III) is a key regulator of lipoprotein metabolism. We investigated whether subspecies of HDL defined by apoC-III are associated with coronary heart disease (CHD).
METHODS: We used immunoaffinity chromatography to measure the apoA-I concentrations of HDL that contains and lacks apoC-III in 2 prospective studies of adults free of CHD. In MESA (Multi-Ethnic Study of Atherosclerosis), 5657 participants (52% women, 52-72 years of age) were followed for risk of CHD from 2000 to 2002 through 2013. In a case-cohort study nested within the DCH study (Danish Diet, Cancer, and Health), 3642 participants (47% women, 51-64 years of age) were followed from 1994 to 1997 through 2010. Subsequently, we conducted a meta-analysis that combined these results with the previously published findings from 2 cohort studies that used similar laboratory methodology to measure lipoproteins, totaling 2997 incident cases.
RESULTS: ApoC-III was found on 6% to 8% of apoA-I. The 2 HDL subspecies showed opposing associations, with risk of CHD in each of the individual cohorts and in the meta-analysis (P heterogeneity between the 2 subspecies <0.01). HDL that contains apoC-III was associated with a higher risk of CHD (pooled relative risk per standard deviation, 1.09; 95% confidence interval, 1.01-1.18), whereas HDL that lacks apoC-III was associated with lower risk (relative risk, 0.76; 95% confidence interval, 0.70-0.83). The relative risk for HDL lacking apoC-III was even more negative than the relative risk for total HDL (relative risk, 0.80; 95% confidence interval, 0.74-0.87).
CONCLUSIONS: Our findings from 4 prospective studies support the hypothesis that apoC-III may mark a subfraction of HDL that is associated with higher risk of CHD. New measures reflecting HDL structure and function may provide novel insights for cardiovascular risk that extend beyond traditional plasma HDL cholesterol concentrations.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  CHD; HDL; biomarker; cohort study; plasma

Mesh:

Substances:

Year:  2017        PMID: 29162611      PMCID: PMC5871573          DOI: 10.1161/CIRCULATIONAHA.117.031276

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Comparison of case-cohort estimators based on data on premature death of adult adoptees.

Authors:  Liselotte Petersen; Thorkild I A Sørensen; Per Kragh Andersen
Journal:  Stat Med       Date:  2003-12-30       Impact factor: 2.373

2.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

3.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.

Authors:  Paolo Zanoni; Sumeet A Khetarpal; Daniel B Larach; William F Hancock-Cerutti; John S Millar; Marina Cuchel; Stephanie DerOhannessian; Anatol Kontush; Praveen Surendran; Danish Saleheen; Stella Trompet; J Wouter Jukema; Anton De Craen; Panos Deloukas; Naveed Sattar; Ian Ford; Chris Packard; Abdullah al Shafi Majumder; Dewan S Alam; Emanuele Di Angelantonio; Goncalo Abecasis; Rajiv Chowdhury; Jeanette Erdmann; Børge G Nordestgaard; Sune F Nielsen; Anne Tybjærg-Hansen; Ruth Frikke Schmidt; Kari Kuulasmaa; Dajiang J Liu; Markus Perola; Stefan Blankenberg; Veikko Salomaa; Satu Männistö; Philippe Amouyel; Dominique Arveiler; Jean Ferrieres; Martina Müller-Nurasyid; Marco Ferrario; Frank Kee; Cristen J Willer; Nilesh Samani; Heribert Schunkert; Adam S Butterworth; Joanna M M Howson; Gina M Peloso; Nathan O Stitziel; John Danesh; Sekar Kathiresan; Daniel J Rader
Journal:  Science       Date:  2016-03-11       Impact factor: 47.728

6.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

7.  Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling.

Authors:  Meliana Riwanto; Lucia Rohrer; Bernd Roschitzki; Christian Besler; Pavani Mocharla; Maja Mueller; Damir Perisa; Kathrin Heinrich; Lukas Altwegg; Arnold von Eckardstein; Thomas F Lüscher; Ulf Landmesser
Journal:  Circulation       Date:  2013-01-24       Impact factor: 29.690

8.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups.

Authors:  Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

9.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark.

Authors:  Anne Tjønneland; Anja Olsen; Katja Boll; Connie Stripp; Jane Christensen; Gerda Engholm; Kim Overvad
Journal:  Scand J Public Health       Date:  2007       Impact factor: 3.021

10.  Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

Authors:  Majken K Jensen; Eric B Rimm; Jeremy D Furtado; Frank M Sacks
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  49 in total

1.  Effects of Replacing Dietary Monounsaturated Fat With Carbohydrate on HDL (High-Density Lipoprotein) Protein Metabolism and Proteome Composition in Humans.

Authors:  Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-26       Impact factor: 8.311

2.  Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies.

Authors:  Jeremy D Furtado; Rain Yamamoto; John T Melchior; Allison B Andraski; Maria Gamez-Guerrero; Patrick Mulcahy; Zeling He; Tianxi Cai; W Sean Davidson; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

3.  Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen
Journal:  Diabetologia       Date:  2019-04-04       Impact factor: 10.122

Review 4.  Emerging Targets for Cardiovascular Disease Prevention in Diabetes.

Authors:  Nathan O Stitziel; Jenny E Kanter; Karin E Bornfeldt
Journal:  Trends Mol Med       Date:  2020-05-15       Impact factor: 11.951

5.  Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Authors:  Ye-Xuan Cao; Hui-Wen Zhang; Jing-Lu Jin; Hui-Hui Liu; Yan Zhang; Rui-Xia Xu; Ying Gao; Yuan-Lin Guo; Cheng-Gang Zhu; Qi Hua; Yan-Fang Li; Raul D Santos; Na-Qiong Wu; Jian-Jun Li
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

6.  Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.

Authors:  Arpita Basu; Ionut Bebu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Matthew J Budoff; Petar Alaupovic; Timothy J Lyons
Journal:  J Lipid Res       Date:  2019-06-15       Impact factor: 5.922

7.  Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men.

Authors:  Leah E Cahill; Frank M Sacks; Eric B Rimm; Majken K Jensen
Journal:  J Lipid Res       Date:  2019-05-29       Impact factor: 5.922

8.  Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

Authors:  Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks
Journal:  JCI Insight       Date:  2018-02-22

9.  Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.

Authors:  Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

Review 10.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.